TNX 100
Alternative Names: 5D12; Anti-CD40 monoclonal antibody 5D12Latest Information Update: 08 Aug 2007
At a glance
- Originator Chiron Corporation
- Developer Tanox
- Class Anti-inflammatories; Monoclonal antibodies
- Mechanism of Action CD40 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Autoimmune disorders; Crohn's disease; Transplant rejection
Most Recent Events
- 03 Aug 2007 Tanox has been acquired by Genentech
- 01 Oct 2004 Discontinued - Phase-I for Crohn's disease in USA (IV)
- 01 Oct 2004 Discontinued - Preclinical for Autoimmune disorders in USA (unspecified route)